Sažetak
Uvod/Cilj. Fankonijeva anemija (FA) je retka nasledna bolest hromozomske nestabilnosti sa specifičnom hipersenzitivnošću ćelija na dejstvo DNK-unakrsno-vezujućih agenasa kao što je diepoksibutan (DEB) i mitomicin C. Cilj rada bio je da se utvrdi hromozomska nestabilnost kod bolesnika sa simptomima FA u Srbiji. Metode. Hromozomska senzitivnost na DEB ispitivana je kod 70 bolesnika klinički suspektnih na FA, koji su dijagnostikovani u Institutu za zdravstvenu zaštitu majke i deteta Srbije „Dr Vukan Čupić”, Beograd i Univerzitetskoj dečijoj klinici, Beograd u periodu 2004–2011. godine. Analiza je sprovedena na netretiranim i DEB-om tretiranim 72-časovnim kulturama limfocita periferne krvi bolesnika i zdravih osoba. Rezultati. Kod 10 bolesnika je uočen povećan broj DEB-om indukovanih hromozomskih prekida (FA grupa), kako u odnosu na ostale pacijente (ne-FA grupa), tako i u odnosu na zdrave kontrole. Procenat aberantnih ćelija u FA grupi kretao se u rasponu 32–82%, dok je raspon u grupi od 58 ne-FA bolesnika iznosio 0–6%, a u kontrolnoj grupi 0–8%. Preostala dva bolesnika pokazala su granični odgovor na DEB (FA* grupa) u poređenju sa zdravim kontrolama. Zaključak. Na osnovu citogenetske analize DEB-om indukovane hromozomske nestabilnosti u limfocitima periferne krvi bolesnika suspektnih na FA, dijagnoza bolesti je postavljena kod njih 10. Postavljanje rane i precizne dijagnoze FA je od velikog značaja za dalje lečenje ovih bolesnika, s obzirom na to da se radi o veoma teškom oboljenju sa letalnim ishodom.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Hisama FM, Tekumalla PK., Weissman SM. Overview of Chromosomal Instability and Aging Mechanisms. In: Hisama FM, Poornima K. Tekumalla, Weissman SM, Martin GM, editor. Chromosomal Instability and Aging: Basic Science and Clinical Implications. New York, Basel: Marcel Dekker, Inc.; 2003. p. 23−41.
Wegner RD, Stumm M. Diagnosis of Chromosomal Instability Syndromes. In: Wegner RD, editor. Diagnostic cytogenetics. Berlin: Springer-Verlag 1999. p. 251−68.
Auerbach AD. Diagnosis of Fanconi Anemia by Diepoxybu-tane Analysis. In Dracopoli NC, Haines JL, Korf BR, Morton CC, Seidman CE, Rosenzweig A, et al, editors. Short Protocols in Human Genetics. New Jersey: John Wiley and Sons, 2004. p. 31−7.
Alter BP. Inherited bone marrow failure syndromes. In: Handin RI, Stossel TP, Lux SE, editors. Blood: Principles and Practice of Hematology. Philadelphia: JB Lippincott 1995. p. 227−91.
Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program 2004; 318−36.
Shaffer LG, Tommerup NS. ISCN 2009. An International System for Cytogenetic Nomenclature. Basel: Karger; 2009.
Huret JL. Fanconi anaemia. Atlas Genet Cytogenet Oncol Haematol 1998; 2(2): 68−9.
Alter BP. Fanconi’s anemia and malignancies. Am J Hematol 1996; 53(2): 99−110.
Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica 2010; 95(8): 1236−40.
Esmer C, Sanchez S, Ramos S, Molina B, Frias S, Carnavale A. DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am J Med Genet A 2004; 124A(1): 35−9.
Liu JM, Buchwald M, Walsh CE, Young NS. Fanconi anemia and novel strategies for therapy. Blood 1994; 12(84): 3995−4007.
Kook H, Cho D, Cho SH, Hong WP, Kim CJ, Park JY, et al. Fan-coni anemia screening by diepoxybutane and mitomicin C tests in Korean children with bone marrow failure syndromes. J Korean Med Sci 1998; (6): 623−8.
Auerbach AD, Rogatko A, Schroeder-Kurth TM. International fan-coni anemia registry: relation of clinical symptoms to diepox-ybutane sensitivity. Blood 1989; 73(2): 391−6.
Ilgin H, Akarsu AN, Bokesoy FI. Cytogenetic and phenotypic findings in Turkish patients with Fanconi anemia. Tr J Med Sci 1999; 29(2): 151−4.
Cho SH, Kook H, Kim GM, Yoon WS, Cho TH, Hwang TJ. A clinical study of Fanconi’s anemia. Korean J Pediatr Hemato-log Oncol 1997; 4(1): 70−7.
Soulier J, Leblanc T, Larghero J, Dastot H, Shimamura A, Guardiola P, et al. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA path-way. Blood 2005; 105(3):1329−36.
Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, et al. Somatic mosaicism in Fanconi anemia: mole-cular basis and clinical significance. Eur J Hum Genet 1997; 5(3):137−48.
Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R, et al. Reverse mosaicism in Fanconi anemia: natural gene ther-apy via molecular self-correction. Cytogenet Genome Res 2002; 98(2−3):126−35.
Youssoufian H. Natural gene therapy and the Darwinian legacy. Nat Genet 1996; 13(3): 255−6.
Castella M, Pujol R, Callén E, Ramírez MJ, Casado JA, Talavera M, et al. Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. J Med Genet 2011; 48(4): 242−50.
Alter BP, Kupfer G. Fanconi anemia. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneRe-views™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1401/ [updated 2013 Feb 07]